ReviewCurrent rheumatology reports2011
Juvenile dermatomyositis.
Review in Current rheumatology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 46 citations in OpenAlex.
- Design of the muscles in motion study: a randomized controlled trial to evaluate the efficacy and feasibility of an individually tailored home-based exercise training program for children and adolescents with juvenile dermatomyositis.BMC musculoskeletal disorders · 2012Trial
- RheumaPain: a multimodal biosignal dataset for objective pain assessment in pediatric rheumatic diseases.Data in brief · 2026Article
- Clinical features, triggers, and risk factors of severe gastrointestinal involvement in anti-NXP2-positive juvenile dermatomyositis: a retrospective cohort study.Pediatric rheumatology online journal · 2026Article
- Neutrophil lymphocyte ratio as a marker of skin disease activity in older children with juvenile dermatomyositis.Pediatric rheumatology online journal · 2025Article
- Juvenile dermatomyositis in Oman: clinical patterns and disease trajectory from a National cohort.Pediatric rheumatology online journal · 2025Article
- Connective tissue disease-associated lung disease in children.Pediatric radiology · 2024Review
- Feasibility of the wingate anaerobic exercise test as a clinical measure in patients with juvenile dermatomyositis.Pediatric rheumatology online journal · 2022Article
- Milk of calcium: A rare manifestation of juvenile dermatomyositis.Archives of rheumatology · 2021Article
- Being on the juvenile dermatomyositis rollercoaster: a qualitative study.Pediatric rheumatology online journal · 2019Article
- Juvenile dermatomyositis: a tertiary center experience.Clinical rheumatology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile dermatomyositis (JDM) is a rare, often chronic autoimmune disease with onset during childhood. It is characterized by weakness in proximal muscles and pathognomonic skin rashes. Although the etiology remains unclear, it has been proposed that JDM is caused by a vasculopathy within the muscle tissue and multiple other organ systems of genetically susceptible individuals, possibly in response to environmental triggers. The goals of treatment include control of the underlying inflammatory myositis and prevention and/or treatment of complications (eg, contractures and calcinosis). Delayed treatment may lead to poorer outcome in terms of disease course and calcinosis. The course in JDM is variable. Monocyclic disease occurs in about one third of patients. These patients have a good response to standard therapy. Early recognition and aggressive immunosuppressive treatment result in improved prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.